Intel stock extends gains after report of possible U.S. government stake
In a challenging market environment, Fortrea Holdings Inc. has seen its stock price touch a 52-week low, dipping to $8.15. According to InvestingPro data, this represents a dramatic fall from the 52-week high of $40.63, though technical indicators suggest the stock is currently in oversold territory. This latest price level reflects a significant downturn for the company, which has experienced a precipitous 1-year change, with its stock value eroding by -79.45%. Investors have been closely monitoring Fortrea Holdings as it navigates through the headwinds that have led to this notable decline in its market valuation. While analyst price targets range from $10 to $15.50, suggesting potential upside, management has been actively buying back shares. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment over the past year. For deeper insights into Fortrea’s technical indicators and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Fortrea Holdings reported disappointing fourth-quarter earnings, with an EPS of $0.18 and revenue of $697 million, both falling short of analyst estimates. The company’s full-year 2025 guidance also missed expectations, forecasting revenues between $2.45 billion and $2.55 billion, below the anticipated $2.74 billion. Fitch Ratings downgraded Fortrea’s Long-Term Issuer Default Rating to ’B’ from ’BB-’, citing a weakening credit profile and reduced near-term growth prospects. The downgrade reflects concerns over Fortrea’s inconsistent revenue growth and high EBITDA leverage, which Fitch predicts will rise to 8.0x in 2025. Analysts from TD Cowen and Citi have also adjusted their outlooks, with TD Cowen lowering Fortrea’s price target to $11 and Citi reducing it to $12, both maintaining neutral ratings. These revisions follow Fortrea’s earnings call, where management highlighted challenges with pre-spin bookings and a product mix leaning towards oncology. Despite the setbacks, Fortrea is implementing cost-saving measures, aiming for net savings of $40-50 million in SG&A expenses. Additionally, Fortrea announced the appointment of Erin L. Russell as a Class II director, bringing extensive experience in finance and healthcare to the board.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.